Dr. Pavlick on the Safety Profile of Cemiplimab in CSCC

CSCC: the role of cemiplimab in clinical data and clinical practiceПодробнее

Neoadjuvant cemiplimab in patients with stage II-IV cutaneous squamous cell carcinomaПодробнее

Experience With Immunotherapy in cSCCПодробнее

Next Steps in the Treatment of cSCCПодробнее

Danny Rischin, MD, considers whether Libtayo (cemiplimab) is a standard of care in advanced CSCCПодробнее

Cemiplimab in Managing Advanced cSCCПодробнее

Dr. Atlas on the Promise of Up-Front Cemiplimab in Locally Advanced CSCCПодробнее

Dr. Pavlick on Longer Follow-Up Data With Cemiplimab in CSCCПодробнее

Dr. Atlas on the Rationale for Cemiplimab in Locally Advanced CSCCПодробнее

Cemiplimab Phase I TrialПодробнее

Dr. Pavlick on Adjuvant Immunotherapy in High-risk MelanomaПодробнее

Cemiplimab prospects: CRC, CSCC & HNSCCПодробнее

Dr. Pavlick on the COLUMBUS Trial in Metastatic MelanomaПодробнее

Advanced CSCC: The New Systemic TherapyПодробнее

Second-Line Systemic Treatment of BCCПодробнее

Managing Patients on Immunotherapy in CSCCПодробнее

Dr. Olszanski on Patient Selection for Cemiplimab Treatment in CSCCПодробнее

Dr. Rischin on the FDA Approval of Cemiplimab for CSCCПодробнее

Cemiplimab in advanced BCCПодробнее